HomeCompareSCVPF vs ABBV

SCVPF vs ABBV: Dividend Comparison 2026

SCVPF yields 3.09% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ABBV wins by $82.1K in total portfolio value
10 years
SCVPF
SCVPF
● Live price
3.09%
Share price
$4.89
Annual div
$0.15
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.2K
Annual income
$0.31
Full SCVPF calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — SCVPF vs ABBV

📍 ABBV pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSCVPFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SCVPF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SCVPF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SCVPF
Annual income on $10K today (after 15% tax)
$263.00/yr
After 10yr DRIP, annual income (after tax)
$0.26/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, ABBV beats the other by $21,055.74/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SCVPF + ABBV for your $10,000?

SCVPF: 50%ABBV: 50%
100% ABBV50/50100% SCVPF
Portfolio after 10yr
$61.3K
Annual income
$12,386.04/yr
Blended yield
20.21%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

SCVPF
Analyst Ratings
1
Buy
Consensus: Buy
Altman Z
1.6
Piotroski
7/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SCVPF buys
0
ABBV buys
0
No recent congressional trades found for SCVPF or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSCVPFABBV
Forward yield3.09%3.06%
Annual dividend / share$0.15$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-50%40.6%
Portfolio after 10y$20.2K$102.3K
Annual income after 10y$0.31$24,771.77
Total dividends collected$312.00$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyBuy

Year-by-year: SCVPF vs ABBV ($10,000, DRIP)

YearSCVPF PortfolioSCVPF Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$10,855$154.70$11,550$430.00$695.00ABBV
2$11,693$78.47$13,472$627.96$1.8KABBV
3$12,551$39.50$15,906$926.08$3.4KABBV
4$13,449$19.81$19,071$1,382.55$5.6KABBV
5$14,401$9.92$23,302$2,095.81$8.9KABBV
6$15,414$4.96$29,150$3,237.93$13.7KABBV
7$16,495$2.48$37,536$5,121.41$21.0KABBV
8$17,651$1.24$50,079$8,338.38$32.4KABBV
9$18,887$0.62$69,753$14,065.80$50.9KABBV
10$20,210$0.31$102,337$24,771.77$82.1KABBV

SCVPF vs ABBV: Complete Analysis 2026

SCVPFStock

The Siam Cement Public Company Limited, together with its subsidiaries, operates in the cement and building materials, chemicals, and packaging businesses in Thailand and internationally. It operates through SCG Cement and Green Solutions, SCG Smart Living and Distributorship and Retail, SCG Décor, SCG Chemicals SCGC, SCGP, and other segments. The SCG Cement and Green Solutions segment produces cement, ready-mixed concrete, precast and post-tension, industrial solutions, waste management services, 3D printing, and advanced materials. Its SCG Smart Living and Distributorship and Retail segment engages in manufacturing of construction materials, including roofing tiles, board and wood substitutions, landscape products, thermal insulation, and autoclaved aerated concrete, as well as housing-related products and services, including solar solutions, fresh air ventilation systems and ventilation systems, modular home building services, and end-to-end roofing solutions; and SCG Distribution and Retail engages in distribution and retailing of cement, building materials, and other home & living products, as well as provides international supply chain solutions, and invests in logistics businesses. The SCG Decor segment engages in production and distributing ceramic tiles, sanitary ware, and related products, services and solutions. Its SCG Chemicals SCGC segment manufactures and sells olefins, polyolefins, vinyl, other chemical products, and providing industrial service and solutions; and SCGP segment engages in integrated packaging of fiber packaging, packaging paper, consumer and performance packaging, and medical supplies and labware; as well as fibrous business consisting of foodservice packaging and pulp and paper products; and recycling of packaging material. The other segment engages in clean energy business, pertinent technologies, and investment in other business. The Siam Cement Public Company Limited was founded in 1913 and is headquartered in Bangkok, Thailand.

Full SCVPF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this SCVPF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SCVPF vs SCHDSCVPF vs JEPISCVPF vs OSCVPF vs KOSCVPF vs MAINSCVPF vs JNJSCVPF vs MRKSCVPF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.